Disease history

History of (or current) coronary artery disease History of carcinoma of the breast (known or suspected)... 

Medical history data may be used in either safety or efficacy analyses. The presence of historical medical conditions may be used as covariates for inferential analyses. Also, medical histories are typically summarized to show that the therapies under study come from study populations with comparable disease histories. Medical histories may be used to determine protocol compliance and to help define a protocol-compliant study population. Medical history is considered a finding from a CDISC perspective. 

Cardiovascular effects Use with caution in patients with cardiovascular disorders including coronary insufficiency, ischemic heart disease, history of stroke, coronary artery disease, cardiac arrhythmias, CHF, and hypertension. 

Speciai risk Use with caution in patients with impaired pulmonary function, particularly those with obstructive pulmonary disease severely impaired cardiac function caused by myocardial disease history of previous liver disease or... 

Full access to the patient so that an appropriate history (e.g., medical/disease history, diet history, concomitant medications, evidence of use for alternative medicines, etc.) can be taken... 

Contraindications Acute hepatic disease, history of hypersensitivity reactions or hepatic injury with previous isoniazid therapy... 

The risk of embolism associated with mechanical heart valves is 2 to 6% per patient per year despite anticoagulation and is highest with valves in the mitral position. Warfarin therapy (INR 2.5 to 3.5) is recommended in these patients. The addition of enteric-coated aspirin (100 mg/d) to warfarin (INR 3.0 to 4.5) in high-risk patients (preoperative atrial fibrillation, coronary artery disease, history of thromboembolism) with mechanical valves decreases the incidence of systemic embolism and death from vascular causes (1.9 vs. 8.5% per year), but increases the risk of bleeding. 

Cardiovascular evaluation and rehabilitation may permit reclassification as low risk Noncardiac atherosclerotic sequelae (peripheral arterial disease, history of stroke, or transient ischemic attacks)... 

Pagni C.A., Altibrandi M.G., Bentivoglio A., Caruso G., Cioni B., Fiorella C., Insola A., Lavano A. et al. Extradural motor cortex stimulation (ECMS) for Parkinson s disease. History and first results by the study group of the Italian neurosurgical society. Acta Neurochir Suppl, 2005, 93, 113-119. 

Offer advice on antibiotic choice(s) based on microbiology results, patient s immunologic state (i.e., neutropenic, type of underlying cancer), patient s infectious disease history (i.e., past infection(s), serology results), institution s microorganism-drug susceptibility record, and institution s microorganism resistance pattern. 

Cardiovascular Does the patient have atrial fibrillation, a coronary artery disease history, or hyperlipidemia increasing stroke risk Could orthostatic hypotension be due to medications for Parkinson s disease treatment Is a medication such as amantadine causing peripheral edema ... 

Effective for 3 months Can be considered for use in women who have seizure disorders, diabetes, hypertension, gall bladder disease, history of cardiovascular or thromboembolic disease and in women who are smokers or lactating Effects quickly reversible Less menstrual cramping and mittelschmerz pain Less menstrual irregularity than other injectable or implantable methods... 

In a pilot study in three premenopausal women with abnormal menstrual cycling patterns and/or menstrual-related disease histories, intake of bladderwrack was associated with increases in menstrual cycle lengths, ranging from an increase of 5.5 to 14 days. Bladderwrack was taken in doses of 0.7 g daily for two menstrual cycles and 1.4 g daily for two additional cycles. Hormone testing in one woman indicated a reduction in 17P-estradiol and an increase in progesterone (Skibola 2004). 

Preiss D, Sattar N, McMurray JJ (2011) A systematic review of event rates in clinical trials in diabetes mellitus the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. Am Heart J 161 210-219 Phung OJ, Schwartzman E, AUen RW, Engel SS, Rajpathak SN (2013) Sulphonylureas and risk of cardiovascular disease systematic review and meta-antilysis. Diabet Med 30 1160-1171 Roumie CL, Hung AM, Greevy RA et al (2012) Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus a cohort study. Ann Intern Med 157 601-610... 

Case Sex, Pathology Disease History and time Symptoms... 

---